ECSP077836A - Compuestos mejorados farmacocinéticamente - Google Patents

Compuestos mejorados farmacocinéticamente

Info

Publication number
ECSP077836A
ECSP077836A EC2007007836A ECSP077836A ECSP077836A EC SP077836 A ECSP077836 A EC SP077836A EC 2007007836 A EC2007007836 A EC 2007007836A EC SP077836 A ECSP077836 A EC SP077836A EC SP077836 A ECSP077836 A EC SP077836A
Authority
EC
Ecuador
Prior art keywords
pharmacocinetic
improved compounds
rock2
methods
rock1
Prior art date
Application number
EC2007007836A
Other languages
English (en)
Inventor
Stewart Campbell
Paul Sweetnam
Alexandra Bartolozzi
Hope Foudoulakis
Brian Kirk
Siya Ram
Original Assignee
Surface Logix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37054004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP077836(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Surface Logix Inc filed Critical Surface Logix Inc
Publication of ECSP077836A publication Critical patent/ECSP077836A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nanotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • General Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Composite Materials (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)

Abstract

La presente invención se relaciona con inhibidores de ROCK1 y ROCK2 y con métodos para modular las propiedades farmacocinéticas y/o farmacodinámicas de esos compuestos. También se proporcionan métodos para inhibir ROCK1 y ROCK2 que son útiles para el tratamiento de la enfermedad.
EC2007007836A 2005-03-25 2007-10-23 Compuestos mejorados farmacocinéticamente ECSP077836A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66516505P 2005-03-25 2005-03-25

Publications (1)

Publication Number Publication Date
ECSP077836A true ECSP077836A (es) 2008-01-23

Family

ID=37054004

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007836A ECSP077836A (es) 2005-03-25 2007-10-23 Compuestos mejorados farmacocinéticamente

Country Status (21)

Country Link
US (6) US8357693B2 (es)
EP (1) EP1865958B1 (es)
JP (2) JP2008534518A (es)
KR (1) KR20080081122A (es)
CN (1) CN101208094B (es)
AU (1) AU2006230159A1 (es)
BR (1) BRPI0622285A2 (es)
CA (1) CA2602254C (es)
CR (1) CR9465A (es)
EA (1) EA022875B1 (es)
EC (1) ECSP077836A (es)
ES (1) ES2549397T3 (es)
GE (1) GEP20105029B (es)
IL (1) IL186299A0 (es)
MX (1) MX2007011859A (es)
NO (1) NO20075145L (es)
NZ (1) NZ562083A (es)
SG (1) SG155163A1 (es)
UA (1) UA96126C2 (es)
WO (1) WO2006105081A2 (es)
ZA (1) ZA200708858B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2584485C (en) 2004-10-20 2013-12-31 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
CR9465A (es) * 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
JP5368792B2 (ja) 2005-07-29 2013-12-18 レスバーロジックス コーポレイション 複合疾患の予防および処置のための薬学的組成物および挿入可能な医療用デバイスによるその送達
AU2007245496A1 (en) 2006-04-26 2007-11-08 Cancer Research Technology Limited Amino-ethyl-amino-aryl (AEAA) compounds and their use
ES2548759T3 (es) * 2006-08-24 2015-10-20 Surface Logix, Inc. Compuestos farmacocinéticamente mejorados
AU2007328336B2 (en) * 2006-12-01 2014-04-17 President And Fellows Of Harvard College Compounds and methods for enzyme-mediated tumor imaging and therapy
DK2118074T3 (en) 2007-02-01 2014-03-10 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
ES2431163T3 (es) 2007-03-01 2013-11-25 Novartis Ag Inhibidores de PIM quinasa y métodos para su uso
JPWO2008156153A1 (ja) * 2007-06-19 2010-08-26 武田薬品工業株式会社 癌の予防・治療剤
KR101629356B1 (ko) 2008-06-26 2016-06-13 리스버로직스 코퍼레이션 퀴나졸리논 유도체의 제조방법
WO2010026124A1 (en) 2008-09-02 2010-03-11 Novartis Ag Picolinamide derivatives as kinase inhibitors
NZ594332A (en) 2009-01-08 2013-09-27 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular disease
EP2406236A4 (en) * 2009-03-09 2013-07-24 Surface Logix Inc RHO KINASE INHIBITORS
KR101709492B1 (ko) 2009-03-18 2017-02-23 리스버로직스 코퍼레이션 신규한 소염제
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
US8658676B2 (en) * 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
RU2640115C2 (ru) 2011-11-01 2017-12-26 Ресверлоджикс Корп. Фармацевтические композиции замещенных хиназолинонов
PE20150194A1 (es) 2012-05-21 2015-02-08 Novartis Ag Novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa
JP6187460B2 (ja) * 2012-06-21 2017-08-30 大正製薬株式会社 ピリドピリミジン−４−オン誘導体
EP2903618B1 (en) * 2012-10-05 2022-06-01 Kadmon Corporation, LLC Rho kinase inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
WO2014159837A1 (en) 2013-03-14 2014-10-02 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins
DK3035936T3 (da) 2013-08-23 2019-06-11 Neupharma Inc Visse kemiske enheder, sammensætninger og fremgangsmåder
EP3270694A4 (en) 2015-02-17 2018-09-05 Neupharma, Inc. Certain chemical entities, compositions, and methods
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
US10167253B2 (en) 2015-06-24 2019-01-01 Nitto Denko Corporation Ionizable compounds and compositions and uses thereof
WO2017091661A1 (en) 2015-11-25 2017-06-01 Strovel Jeffrey William Bicyclic bet bromodomain inhibitors and uses thereof
EP3497087B1 (en) * 2016-08-15 2021-11-10 Neupharma, Inc. Pyrrolo[1,2-c]pyrimidine, imidazo[1,5-c]pyrimidine, quinazoline, purine and imidazo[1,5-a][1,3,5]triazine derivatives as tyrosine kinase inhibitors for the treatment of cancer
US11071735B2 (en) 2017-04-28 2021-07-27 Kadmon Corporation, Llc Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors
AU2018294054B2 (en) * 2017-06-30 2022-05-26 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
WO2019000683A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
CN110573501B (zh) 2017-06-30 2023-09-29 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
WO2019046795A1 (en) 2017-09-03 2019-03-07 Angion Biomedica Corp. VINYL HETEROCYCLES AS INHIBITORS OF RHO (ROCK) ASSOCIATED BISPIRALIZED KINASE
US10815250B2 (en) 2018-02-06 2020-10-27 Ideaya Biosciences, Inc. AhR modulators
US11345678B2 (en) 2018-04-18 2022-05-31 Medshine Discovery Inc. Benzopyrazole compound used as RHO kinase inhibitor
US12398118B2 (en) 2018-11-09 2025-08-26 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and use thereof
EP3958867B1 (en) 2019-04-24 2024-06-26 Convergene Llc Small molecule bromodomain inhibitors and uses thereof
US11702400B2 (en) 2019-10-18 2023-07-18 Medshine Discovery Inc. Salt types, crystal forms, and preparation methods for benzopyrazole compounds as RHO kinase inhibitors
CN114746412A (zh) * 2019-12-27 2022-07-12 广东东阳光药业有限公司 Kd-025的新晶型及其制备方法
IL300040A (en) * 2020-07-22 2023-03-01 Teva Pharmaceuticals Int Gmbh Crystalline forms of blomosodil and salts of blomosodil
WO2022042666A1 (zh) * 2020-08-28 2022-03-03 杭州邦顺制药有限公司 选择性rock2激酶抑制剂
WO2022170864A1 (zh) * 2021-02-09 2022-08-18 苏州科睿思制药有限公司 Belumosudil甲磺酸盐的晶型及其制备方法和用途
CN114573566B (zh) * 2021-03-04 2023-05-30 杭州邦顺制药有限公司 选择性rock2激酶抑制剂
CN115124514A (zh) * 2021-03-26 2022-09-30 广东东阳光药业有限公司 Kd-025的共晶及其制备方法
US20240343712A1 (en) 2021-07-16 2024-10-17 Sandoz Ag Solid-state forms of 2-(3-(4-(1h-indazol-5-ylamino)quinazolin-2-yl)phenoxy)-n-isopropylacetamide methane sulfonic acid salt
KR20250003657A (ko) 2022-04-19 2025-01-07 카드몬 코포레이션, 엘엘씨 만성 폐 동종이식편 기능장애 치료를 위한 벨루모수딜
WO2024000060A1 (en) * 2022-06-30 2024-01-04 Apotex Inc Salts of belumosudil, crystalline forms and pharmaceutical compositions thereof and their use in the treatment of chronic graft-versus-host disease
CA3178085A1 (en) 2022-07-14 2024-01-14 Kadmon Corporation, Llc Belumosudil metabolites and uses thereof in the treatment of chronic graft-versus-host disease
CA3178086A1 (en) 2022-07-14 2024-01-14 Kadmon Corporation, Llc Methods of administering belumosudil for treatment of chronic graft versus host disease in patient subpopulations
AU2022468990A1 (en) 2022-07-14 2025-02-27 Kadmon Corporation, Llc Methods of administering belumosudil in combination with cyp3a inducers and/or proton pump inhibitors
MA71428A (fr) 2022-07-14 2025-04-30 Kadmon Corporation, Llc Procédés d'administration de belumosudil pour le traitement de la maladie chronique du greffon contre l'hôte
CN115385899B (zh) * 2022-09-08 2024-04-02 药康众拓(江苏)医药科技有限公司 ROCK2抑制剂belumosudil的氘代药物及用途
WO2024063770A1 (en) 2022-09-21 2024-03-28 Kadmon Corporation, Llc Liquid formulation of belumosudil
IL320719A (en) 2022-11-11 2025-07-01 Assia Chem Ind Ltd Solid forms of blomosodil and processes for obtaining blomosodil
EP4626434A1 (en) 2022-11-29 2025-10-08 Kadmon Corporation, LLC Solid dispersion comprising amorphous 2-[3-[4-(lh-indazol-5- ylamino)quinazolin-2-yl]phenoxy]-n-propan-2-yl-acetamide
JP2026500164A (ja) 2022-12-09 2026-01-06 カドモン コーポレイション，リミティド ライアビリティ カンパニー 多発性骨髄腫の治療のためのベルモスジルの投与方法
CN116444443B (zh) * 2023-03-15 2025-09-05 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 一种苯甲酰-喹唑啉酮衍生物及其制备方法与应用
WO2025017499A1 (en) 2023-07-17 2025-01-23 Graviton Bioscience Bv Formulations and uses of rock2 inhibitors for als
AU2024352423A1 (en) 2023-09-28 2026-05-14 Graviton Pharmaceuticals B.V. Therapy for treating type 1 diabetes using rock2 and dyrk1 inhibitors
WO2025069009A1 (en) 2023-09-29 2025-04-03 Graviton Bioscience Bv Rock2 inhibitors in the treatment of obesity
WO2025076350A1 (en) 2023-10-06 2025-04-10 Kadmon Corporation, Llc Methods of administering belumosudil in combination with transport protein substrates
CN119954779A (zh) * 2023-11-07 2025-05-09 江苏东科康德药业有限公司 甲磺酸贝舒地尔杂质、制备及检测方法
WO2025110992A1 (en) 2023-11-21 2025-05-30 Kadmon Corporation, Llc Method of administering belumosudil for patient subpopulations with hepatic impairment
WO2025184133A1 (en) 2024-02-29 2025-09-04 Kadmon Corporation, Llc Methods of treating chronic graft versus host disease with belumosudil after ceasing administration of ruxolitinib
CN119751424B (zh) * 2025-01-04 2025-12-05 重庆圣华曦药业股份有限公司 一种合成甲磺酸贝舒地尔的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0836605B1 (en) * 1995-07-06 2002-02-06 Novartis AG Pyrrolopyrimidines and processes for the preparation thereof
NZ334613A (en) 1996-08-12 2002-02-01 Welfide Corp Pharmaceutical agents comprising Rho kinase inhibitor
TWI284642B (en) * 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
KR100818061B1 (ko) * 2000-03-16 2008-04-01 미쯔비시 웰 파마 가부시키가이샤 아미드 화합물 및 그의 용도
DE60125026T2 (de) * 2000-03-23 2007-06-28 Takeda Pharmaceutical Co. Ltd. Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung
US6699665B1 (en) 2000-11-08 2004-03-02 Surface Logix, Inc. Multiple array system for integrating bioarrays
JP4329003B2 (ja) * 2001-03-23 2009-09-09 バイエル コーポレイション Ｒｈｏキナーゼ阻害剤
TWI336328B (en) * 2001-03-23 2011-01-21 Bayer Healthcare Llc Rho-kinase inhibitors
WO2003012392A2 (en) 2001-07-27 2003-02-13 Surface Logix, Inc. Resealable and sealable devices for biochemical assays
AU2002329864B2 (en) 2001-08-27 2008-07-31 Surface Logix, Inc. Immobilization of biological molecules onto surfaces coated with monolayers
JP2003221386A (ja) * 2001-11-26 2003-08-05 Takeda Chem Ind Ltd 二環性誘導体、その製造法およびその用途
DE10162435A1 (de) 2001-12-19 2003-07-17 Joerg Lahann Verfahren zur Erzeugung von Oberflächenbeschichtungen, die die Adsorption von Proteinen bzw. die Adhäsion von Bakterien und/oder Zellen vermindern
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
GB0206860D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
CA2506799A1 (en) * 2002-11-21 2004-06-10 Eli Lilly And Company Mixed lineage kinase modulators
GB0301016D0 (en) * 2003-01-16 2003-02-19 Univ London Treatment of benign prostatic hyperplasia
US20050014783A1 (en) 2003-05-29 2005-01-20 Schering Aktiengesellschaft Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
WO2004108136A1 (en) * 2003-06-04 2004-12-16 Vernalis (Cambridge) Limited Triazolo `1 , 5-a!pyrimidines and their use in medicine
WO2005020921A2 (en) * 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
ES2372694T3 (es) * 2003-10-15 2012-01-25 OSI Pharmaceuticals, LLC Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
CA2598270A1 (en) * 2005-02-18 2006-08-24 Surface Logix, Inc. Methods of making pharmacokinetically improved compounds comprising functional residues or groups and pharmaceutical compositions comprising said compounds
KR20080016531A (ko) * 2005-02-18 2008-02-21 서피스 로직스, 인크. 약동학적으로 개선된 화합물
CR9465A (es) * 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
ES2548759T3 (es) * 2006-08-24 2015-10-20 Surface Logix, Inc. Compuestos farmacocinéticamente mejorados

Also Published As

Publication number Publication date
ES2549397T3 (es) 2015-10-27
CN101208094A (zh) 2008-06-25
JP2015193639A (ja) 2015-11-05
EA022875B1 (ru) 2016-03-31
IL186299A0 (en) 2008-01-20
US20130131047A1 (en) 2013-05-23
WO2006105081A3 (en) 2007-05-10
SG155163A1 (en) 2009-09-30
BRPI0622285A2 (pt) 2011-08-16
US20180072710A1 (en) 2018-03-15
CA2602254C (en) 2015-03-24
ZA200708858B (en) 2009-09-30
CA2602254A1 (en) 2006-10-05
WO2006105081A2 (en) 2006-10-05
UA96126C2 (ru) 2011-10-10
US20100144707A1 (en) 2010-06-10
US20150344464A1 (en) 2015-12-03
US20210017166A1 (en) 2021-01-21
AU2006230159A1 (en) 2006-10-05
KR20080081122A (ko) 2008-09-08
US10570123B2 (en) 2020-02-25
NZ562083A (en) 2010-12-24
EP1865958A2 (en) 2007-12-19
NO20075145L (no) 2007-11-28
GEP20105029B (en) 2010-06-25
EP1865958A4 (en) 2012-01-25
US8916576B2 (en) 2014-12-23
CR9465A (es) 2008-06-19
MX2007011859A (es) 2008-04-04
EA200702048A1 (ru) 2008-04-28
JP2008534518A (ja) 2008-08-28
CN101208094B (zh) 2014-10-15
JP5956661B2 (ja) 2016-07-27
US8357693B2 (en) 2013-01-22
US9440961B2 (en) 2016-09-13
US20190177311A1 (en) 2019-06-13
EP1865958B1 (en) 2015-07-08

Similar Documents

Publication Publication Date Title
CR9465A (es) Compuestos mejorados farmacocineticamente
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
UY32123A (es) Derivados de n - (sustituido) - 4 - (but-2-iniloxi) - benzamida, sus racematos, diastereòmeros, enantiòmeros y las sales de los mismos y aplicaciones
GT200900027A (es) Compuestos organicos
ECSP099525A (es) Inhibidores de mek
PA8719401A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
CO6331340A2 (es) Pirrolo-pirimidinas y pirrolo piridinas
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
CY1108275T1 (el) Χημικες ενωσεις
CR11107A (es) INDOLES SUSTITUIDOS EN LA POSICION 7 INHIBIDORES DE Mcl-1
EA201070247A1 (ru) Ингибиторы протеасом
UA87153C2 (ru) Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы
CU23831B1 (es) Compuestos de pirrolo-pirimidina
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
CR20130455A (es) Composiciones para el tratamiento de tumores
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
CR20110202A (es) Antagonistas de la via hedgehog de ftalazina disustituida
PA8667201A1 (es) Nuevos compuestos farmaceuticos
ATE471324T1 (de) Triazolophthalazine
SV2011003839A (es) Agentes antifungicos
CY1111899T1 (el) Καινοφανη παραγωγα πυρρολης με δραστηριοτητα αναστολεα της απακετυλασης της ιστονης